[Improving efficacy of cancer immunotherapy through targeting of macrophages]

Med Sci (Paris). 2019 Mar;35(3):207-209. doi: 10.1051/medsci/2019043. Epub 2019 Apr 1.

[Article in French]

Authors

Elisa Peranzoni¹, Emmanuel Donnadieu²

Affiliations

¹ Inserm, U1016, Institut Cochin, 22, rue Méchain, 75014 Paris, France - CNRS, UMR8104, Paris, France - Université Paris Descartes, Sorbonne Paris Cité, Paris, France - Institut de Recherches Servier, 125, Chemin de Ronde, 78290 Croissy-sur-Seine, France.
² Inserm, U1016, Institut Cochin, 22, rue Méchain, 75014 Paris, France - CNRS, UMR8104, Paris, France - Université Paris Descartes, Sorbonne Paris Cité, Paris, France.

PMID: 30931902
DOI: 10.1051/medsci/2019043

No abstract available

Publication types

News

MeSH terms

Antineoplastic Agents, Immunological / administration & dosage*
Cancer Vaccines / administration & dosage
Combined Modality Therapy
Humans
Immunotherapy / methods*
Macrophage Colony-Stimulating Factor / antagonists & inhibitors*
Macrophage Colony-Stimulating Factor / immunology
Macrophages / drug effects*
Macrophages / pathology*
Macrophages / physiology
Molecular Targeted Therapy
Neoplasms / immunology
Neoplasms / pathology
Neoplasms / therapy*
Treatment Outcome

Substances

Antineoplastic Agents, Immunological
CSF1 protein, human
Cancer Vaccines
Macrophage Colony-Stimulating Factor